Report
Petrelintide reportedly produced 10.7% average weight loss over 42 weeks in a Phase II trial
Medical Xpress reports 1.7% average weight loss with placebo and says petrelintide still needs Phase III confirmation.
TLDR
Medical Xpress reports that petrelintide produced 10.7% average weight loss over 42 weeks in a Phase II trial, compared with 1.7% for placebo. It describes the drug as a potential obesity treatment that still needs Phase III confirmation.
Combined views
2K
2 Sources, first seen 6h ago
2 likes2 reposts